Skip to main content
. 2020 Jul 27;46(Suppl 1):50–61. doi: 10.1590/S1677-5538.IBJU.2020.S106

Table 3. Management of non metastatic castration- resistant PCa during the COVID-19 era.

Tumor Stage Recommendations Comments
Nonmetastatic castration- resistant prostate cancer Consider combination castration therapy with the new hormonal treatments (apalutamide, darolutamide, enzalutamide) in high selected patients. These drugs have demonstrated benefits in terms of metastatic free survival in patients with PSA-DT < 10 months ( 1 , 15 , 16 ).

PSA-DT = Prostate Specific Antigen - Doubling Time